A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

Completed · Phase 2 · Has a placebo group

Conditions studied: Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis

In brief

This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis.

Key facts

Study ID
NCT02784444
Run by
Cirius Therapeutics, Inc.
People needed
392
Starts
2016-09-14
Expected to finish
2019-06-01
Last updated by the study team
2020-09-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.